The number of moles, or nevi, a patient had was not related to the likelihood that they had melanoma, according to the results of a new study published in JAMA Dermatology. In fact, the study found that most patients with melanoma had very few nevi and no atypical nevi.
MRV Research
Many Melanoma Patients May Have Few Moles
Checking out the moles on your skin is a common way to look for the deadly skin cancer melanoma, but a new study shows that many people with melanoma may have few moles.
In the study, researchers looked at about 560 people with melanoma and found that 66 percent of them had 20 or fewer moles.
TriMixDC-MEL Plus Ipilimumab Active in Pretreated Advanced Melanoma
Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) in combination with ipilimumab was tolerable and resulted in highly durable responses in patients with pretreated advanced melanoma, a study published in the Journal of Clinical Oncology has shown.1
Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma
With 2 different BRAF/MEK combination regimens approved by the FDA, as well as an immunotherapy combination, treatment and sequencing decisions for metastatic BRAF-mutated melanoma can be difficult, says Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, codirector of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center.